公开(公告)号：US07790173B2

公开(公告)日：2010-09-07

申请号：US12067129

申请日：2006-09-18

申请人： Laura Lazo Vázquez ,  Lisset Hermida Cruz ,  Carlos López Abarrategui ,  Beatriz de la Caridad Sierra Vázquez ,  Susana Vázquez Ramundo ,  Iris Valdez Prado ,  Gerardo Enrique Guillen Nieto ,  Maria Guadalupe Guzmán Tirado ,  Aida Zulueta Morales

发明人： Laura Lazo Vázquez ,  Lisset Hermida Cruz ,  Carlos López Abarrategui ,  Beatriz de la Caridad Sierra Vázquez ,  Susana Vázquez Ramundo ,  Iris Valdez Prado ,  Gerardo Enrique Guillen Nieto ,  Maria Guadalupe Guzmán Tirado ,  Aida Zulueta Morales

IPC分类号： A61K39/00 ,  A61K39/12

CPC分类号： A61K39/12 ,  A61K2039/55505 ,  A61K2039/55566 ,  C07K14/005 ,  C12N2770/24122 ,  C12N2770/24134 ,  Y02A50/386

摘要： This invention describes a pharmaceutical compound which has the capsid protein of Dengue virus and which is capable of inducing, in the receptor, a protective immune response before the viral challenge, without inducing the Ab-dependent enhancement phenomenon.

摘要翻译： 本发明描述了具有登革热病毒衣壳蛋白的能够在病毒攻击之前在受体中诱导保护性免疫应答而不诱导依赖于Ab的增强现象的药物化合物。

公开(公告)号：US20070166333A1

公开(公告)日：2007-07-19

申请号：US10577000

申请日：2004-11-03

申请人： Olivia Niebla Perez ,  Rolando Pajon Feyt ,  Sonia Gonzalez Blanco ,  Alejandro Martin Dunn ,  Maite Delgado Espina ,  Hilda Garay Perez ,  Gerardo Guillen Nieto

发明人： Olivia Niebla Perez ,  Rolando Pajon Feyt ,  Sonia Gonzalez Blanco ,  Alejandro Martin Dunn ,  Maite Delgado Espina ,  Hilda Garay Perez ,  Gerardo Guillen Nieto

IPC分类号： A61K39/095 ,  C12N15/74 ,  C12N1/21

CPC分类号： C07K14/22 ,  A61K39/00

摘要： Method for the insertion of protein antigens, of recombinant or synthetic origin, in outer membrane vesicles of Gram-negative bacteria without disruption of the vesicle structure, therefore maintaining the immunogenicity and immunostimulatory properties of said vesicles, and with the reported advantage that the immune response generated against the incorporated antigen is superior to the one generated when the antigen is administered alone. The resultant vaccine formulations are useful to increase protective capacity of existing vaccines and allow to extend it against different pathogens, in diseases of bacterial, viral, cancerous or other etiology. The referred formulations are applicable in the pharmaceutical industry as vaccines for therapeutic and preventive use in humans.

摘要翻译： 在革兰氏阴性细菌的外膜囊泡中插入重组或合成来源的蛋白质抗原的方法，而不破坏囊泡结构，从而保持所述囊泡的免疫原性和免疫刺激性质，并且报告的优点是免疫应答 针对所掺入的抗原产生的抗原优于单独施用抗原时产生的抗原。 所得的疫苗制剂可用于增加现有疫苗的保护能力，并允许其在细菌，病毒，癌性或其它病因学疾病中扩展到不同的病原体。 所提及的制剂在制药工业中可用作人类治疗和预防用途的疫苗。

公开(公告)号：US20060193853A1

公开(公告)日：2006-08-31

申请号：US10539172

申请日：2003-12-22

申请人： Eddy Fuentes ,  Roberto Baker ,  Eulogio Vazquez ,  Jesus Barranco ,  Franklin Aguilar ,  Niurka More ,  Lesvia Aguilera ,  Hector Dominguez ,  Yovisleidys Saez ,  Gerardo Guillen Nieto ,  Glay Santiago

发明人： Eddy Fuentes ,  Roberto Baker ,  Eulogio Vazquez ,  Jesus Barranco ,  Franklin Aguilar ,  Niurka More ,  Lesvia Aguilera ,  Hector Dominguez ,  Yovisleidys Saez ,  Gerardo Guillen Nieto ,  Glay Santiago

IPC分类号： A61K39/395 ,  A61K38/24 ,  A61K38/25 ,  A61K38/17

CPC分类号： A61K39/0011 ,  A61K39/395 ,  A61K2039/6037 ,  A61K2039/6068 ,  A61K2039/6081

摘要： The invention relates to the field of immunology, endocrinology and oncology and, in particular, the generation of a combined immune response to determined growth factors and hormones. A synergic effect, outlined herein, between growth regulating factors (EGF, TGF and VEGF) and hormones involved in the sexual hormones release cascade or reproduction (GnRH, LH, FSH) stimulates the anti-tumor response which is expressed as a reduction in the tumor mass and an increase in the survival time.

摘要翻译： 本发明涉及免疫学，内分泌学和肿瘤学领域，特别是对确定的生长因子和激素的组合免疫应答的产生。 生长调节因子（EGF，TGF和VEGF）和参与性激素释放级联或繁殖（GnRH，LH，FSH）的激素之间的协同作用刺激抗肿瘤反应，其表达为 肿瘤块和生存时间增加。

公开(公告)号：US08569470B2

公开(公告)日：2013-10-29

申请号：US12739658

申请日：2008-10-17

申请人： Diógenes Quintana Vázquez ,  Tamara Menendez Medina ,  Anabel Álvarez Acosta ,  Yoelys Cruz Leal ,  Gerardo Enrique Guillen Nieto

发明人： Diógenes Quintana Vázquez ,  Tamara Menendez Medina ,  Anabel Álvarez Acosta ,  Yoelys Cruz Leal ,  Gerardo Enrique Guillen Nieto

IPC分类号： C07H21/04 ,  A61K39/10

CPC分类号： G01N33/56911 ,  A61K39/00 ,  A61K39/099 ,  A61K2039/522 ,  A61K2039/523 ,  A61K2039/53 ,  C07K14/235 ,  Y02A50/466

摘要： The present invention is related with the field of Biomedicine. It comprises the engineering of the Pertactin protein (Prn) and using it as part of bacterial vaccines, and more precisely, as part of acellular vaccines against Bordetella pertusis. The engineered Prn molecules comprise on their structure polimorfisms from different B. pertussis strains, and induce immune responses with protective capacity and opsonophagocytic activity when assayed as vaccines, higher than that generated by other pre-existing vaccines. The engineered Prn variants of the present invention are applicable in human and veterinary medicine.

摘要翻译： 本发明涉及生物医学领域。 它包括Pertactin蛋白（Prn）的工程，并将其用作细菌疫苗的一部分，更确切地说，它是作为针对博德氏菌的无细胞疫苗的一部分。 工程化的Prn分子在其结构上包括来自不同的百日咳杆菌菌株的结构，并且当测定为疫苗时诱导具有保护能力和调理吞噬活性的免疫应答，高于其他预先存在的疫苗产生的疫苗。 本发明的工程化Prn变体可应用于人兽药。

公开(公告)号：US20110250196A1

公开(公告)日：2011-10-13

申请号：US13121915

申请日：2009-09-30

申请人： Jesus Arturo Junco Barranco ,  Osvaldo Reyes Acosta ,  Eddy Emilio Bover Fuentes ,  Franklin Fuentes Aguilar ,  Eulogio Pimentel Vazquez ,  Roberto Basulto Baker ,  Gerardo Enrique Guillen Nieto ,  Yovisleidys Lopez Saez ,  Hilda Elisa Garay Perez ,  Lesvia Calzada Aguilera ,  Maria Castro Santana ,  Niurka Oneysi Arteaga More ,  Luis Alberto Aguero Barrocal

发明人： Jesus Arturo Junco Barranco ,  Osvaldo Reyes Acosta ,  Eddy Emilio Bover Fuentes ,  Franklin Fuentes Aguilar ,  Eulogio Pimentel Vazquez ,  Roberto Basulto Baker ,  Gerardo Enrique Guillen Nieto ,  Yovisleidys Lopez Saez ,  Hilda Elisa Garay Perez ,  Lesvia Calzada Aguilera ,  Maria Castro Santana ,  Niurka Oneysi Arteaga More ,  Luis Alberto Aguero Barrocal

IPC分类号： A61K39/395 ,  A61P35/00 ,  A61P37/04 ,  A61K39/00

CPC分类号： A61K39/0011 ,  A61K38/09 ,  A61K39/0006 ,  A61K47/48261 ,  A61K47/4833 ,  A61K47/6415 ,  A61K47/646 ,  A61K2039/585 ,  A61K2039/6037 ,  A61K2300/00

摘要： A pharmaceutical composition using natural gonadotropin-releasing hormone (GnRH), and/or some of its mimetic peptides, indistinctly bound by its amino or carboxyl extremes to a carrier molecule; in one case by its carboxyl extreme and in the other case by the amino terminal extreme, thus eliciting a faster and more potent immunological response against the endogenous GnRH hormone. This finally leads to the ablation of the GnRH and consequently of the rest of the involved hormones in the stream GnRH/LH-FSH/Testosterone-(estrogens). An advantage of this formulation consists on facilitating the exposition to the immune system of a greater number of epitopes of the GnRH or its mimetics, minimizing thus the steric hindrance produced by the carriers. This invention has a direct application in the castration of pets and animals of economic interest, in the control of human fertility as well as in the treatment of hormone-sensitive tumors, such as that of the prostate, the breast, ovary, the endometry, testicles, hypophysis, salivary glands and other kinds of human tumors.

摘要翻译： 使用天然促性腺激素释放激素（GnRH）和/或其一些模拟肽的药物组合物，其不明显地被其氨基或羧基末端与载体分子结合; 在一种情况下其羧基末端，另一种情况下由氨基末端极端，从而引发对内源GnRH激素的更快更有效的免疫应答。 这最终导致消化GnRH，从而导致流GnRH / LH-FSH /睾酮（雌激素）中涉及的其他激素的消融。 该制剂的优点在于促进免疫系统暴露于更多数量的GnRH或其模拟物的表位，从而最小化载体产生的空间位阻。 本发明直接应用于经济兴趣的宠物和动物的阉割，控制人的生育能力以及治疗激素敏感性肿瘤，如前列腺，乳腺，卵巢， 睾丸，垂体，唾液腺等多种人体肿瘤。

公开(公告)号：US20110070265A1

公开(公告)日：2011-03-24

申请号：US12739658

申请日：2008-10-17

申请人： Diógenes Quintana Vázquez ,  Tamara Menendez Medina ,  Anabel Álvarez Acosta ,  Yoelys Cruz Leal ,  Gerardo Enrique Guillen Nieto

发明人： Diógenes Quintana Vázquez ,  Tamara Menendez Medina ,  Anabel Álvarez Acosta ,  Yoelys Cruz Leal ,  Gerardo Enrique Guillen Nieto

IPC分类号： A61K39/10 ,  C12N15/31 ,  C07K14/235 ,  C12N15/63 ,  C12Q1/68 ,  A61P37/04 ,  A61P31/04

CPC分类号： G01N33/56911 ,  A61K39/00 ,  A61K39/099 ,  A61K2039/522 ,  A61K2039/523 ,  A61K2039/53 ,  C07K14/235 ,  Y02A50/466

摘要： The present invention is related with the field of Biomedicine. It comprises the engineering of the Pertactin protein (Prn) and using it as part of bacterial vaccines, and more precisely, as part of acellular vaccines against Bordetella pertusis. The engineered Prn molecules comprise on their structure polimorfisms from different B. pertussis strains, and induce immune responses with protective capacity and opsonophagocytic activity when assayed as vaccines, higher than that generated by other pre-existing vaccines. The engineered Prn variants of the present invention are applicable in human and veterinary medicine.

摘要翻译： 本发明涉及生物医学领域。 它包括Pertactin蛋白（Prn）的工程，并将其用作细菌疫苗的一部分，更确切地说，它是作为针对博德氏菌的无细胞疫苗的一部分。 工程化的Prn分子在其结构上包括来自不同的百日咳杆菌菌株的结构，并且当测定为疫苗时诱导具有保护能力和调理吞噬活性的免疫应答，高于其他预先存在的疫苗产生的疫苗。 本发明的工程化Prn变体可应用于人兽药。

公开(公告)号：US07361638B2

公开(公告)日：2008-04-22

申请号：US10220750

申请日：2001-12-17

申请人： Jorge Berlanga Acosta ,  Gerardo Enrique Guillen Nieto ,  Diana Garcia Del Barco Herrera ,  Julio Raul Fernandez Masso ,  Mario Pablo Estrada Garcia ,  Isabel Guillen Perez ,  Jose Suarez Alba ,  Rebeca Martinez Rodriguez

发明人： Jorge Berlanga Acosta ,  Gerardo Enrique Guillen Nieto ,  Diana Garcia Del Barco Herrera ,  Julio Raul Fernandez Masso ,  Mario Pablo Estrada Garcia ,  Isabel Guillen Perez ,  Jose Suarez Alba ,  Rebeca Martinez Rodriguez

IPC分类号： A61K38/08 ,  A61K38/18 ,  C07K14/485 ,  C07K14/495

CPC分类号： A61K38/1841 ,  A61K38/08 ,  A61K38/1808 ,  A61K38/25 ,  A61K38/27 ,  A61K2300/00

摘要： This invention relates to a medicine for humans, and particularly to a pharmaceutical combination comprising Epidermal Growth Factor (EGF) and Growth Hormone secretagogue hexapeptide (GHRP) for use in preventing tissue damage due to blood flow suppression by enhancing tissue repair following ischemic damage. The aforementioned combination may be applied as a single pharmaceutical composition. Alternatively, an individual may also receive both EGF and GHRP in a separate manner but within a single therapeutic regime to enhance cellular survival when organs are subjected to blood flow deprivation for a critical period of time. This combination attenuates reactive oxygen species (ROS) formation and its associated cytotoxicity. It is also useful in promoting cellular survival when tissue or organs are exposed to prolonged ischemic periods. The combination is useful as a prophylactic agent in those subjects prone to multiple organ failure (MOF) such as burn victims, multiple trauma patients, hypoxic neonates, acute respiratory distress syndrome patients, and necrotizing enterocolitis patients.

摘要翻译： 本发明涉及用于人的药物，特别涉及包含表皮生长因子（EGF）和生长激素促分泌素六肽（GHRP）的药物组合，用于通过增强缺血性损伤后的组织修复来预防由于血流抑制引起的组织损伤。 上述组合可以作为单一药物组合物使用。 或者，个体也可以以单独的方式接受EGF和GHRP，但是在单一治疗方案内，以便当器官在关键时间段内遭受血流剥夺时增强细胞存活。 这种组合减弱活性氧（ROS）形成及其相关的细胞毒性。 当组织或器官暴露于长时间缺血期时，它也可促进细胞存活。 该组合在易受多器官功能衰竭（MOF）的受试者，如烧伤受试者，多发性创伤患者，缺氧新生儿，急性呼吸窘迫综合征患者和坏死性小肠结肠炎患者中的预防剂是有用的。

公开(公告)号：US20070141081A1

公开(公告)日：2007-06-21

申请号：US11705696

申请日：2007-02-13

申请人： Lisset Cruz ,  Rayner Diaz ,  Laura Vazquez ,  Aida Morales ,  Carlos Abarrategui ,  Iris Prado ,  Ricardo Silva Rodriguez ,  Glay Santiago ,  Gerardo Guillen Nieto ,  Maria Guzman Tirado ,  Beatriz de la Sierra Vazquez ,  Raul Espinosa Perez

发明人： Lisset Cruz ,  Rayner Diaz ,  Laura Vazquez ,  Aida Morales ,  Carlos Abarrategui ,  Iris Prado ,  Ricardo Silva Rodriguez ,  Glay Santiago ,  Gerardo Guillen Nieto ,  Maria Guzman Tirado ,  Beatriz de la Sierra Vazquez ,  Raul Espinosa Perez

IPC分类号： C12P19/34 ,  A61K39/12

CPC分类号： C07K14/005 ,  A61K39/00 ,  C07K2319/00 ,  C12N9/0006 ,  C12N2770/24122 ,  Y02A50/386

摘要： The present invention is related to the obtaining of chimeric chains coding for proteins capable of inducing, in the recipient, a serotype-specific and protective humoral immune response against the infection by the Dengue virus, thus eliminating the effects of the serotype-nonespecific viral immunoenhancement that causes hemorrhagies and clinical complications described for this kind of pathology. These chimeric chains of nucleic acids are composed by the specific combination of fragments belonging to the gene of a mutated protein from Neisseria meningitidis with dehydrogenase activity and fragments that codify for a region of the envelope (E) protein from the Dengue virus which, when inserted to an expression vector, give rise to chimeric proteins with particular properties. The resultant chimeric molecules from this invention are applicable to the pharmaceutical industry for the obtaining of vaccine preparations and diagnostic means of high serotype-specificity to be used in humans.

摘要翻译： 本发明涉及获得编码蛋白质的蛋白质的嵌合链，其能够在受体中诱导抗登革病毒感染的血清型特异性和保护性体液免疫应答，从而消除血清型非特异性病毒免疫增强的作用 导致这种病理描述的出血和临床并发症。 核酸的这些嵌合链由来自脑膜炎奈瑟氏球菌与脱氢酶活性的突变蛋白质的基因的片段的特异性组合和编入来自登革病毒的包膜（E）蛋白的区域的片段组成，当插入时 表达载体，产生具有特定性质的嵌合蛋白。 所得到的本发明的嵌合分子适用于获得用于人类的疫苗制剂和高血清型特异性的诊断方法的制药工业。

公开(公告)号：US20050107294A1

公开(公告)日：2005-05-19

申请号：US10499457

申请日：2002-12-04

申请人： Jorge Acosta ,  Jose Fernandez Montequin ,  Calixto Valdes Perez ,  Neobalis Perez ,  Ingrid Constantin ,  Hector Milian ,  Larissa Corvea ,  Gerardo Guillen Nieto ,  Luis Martinez ,  Leonardo Canan-Haden Frias ,  Haydee Geronimo Perez ,  Jorge Sotolongo Pena

发明人： Jorge Acosta ,  Jose Fernandez Montequin ,  Calixto Valdes Perez ,  Neobalis Perez ,  Ingrid Constantin ,  Hector Milian ,  Larissa Corvea ,  Gerardo Guillen Nieto ,  Luis Martinez ,  Leonardo Canan-Haden Frias ,  Haydee Geronimo Perez ,  Jorge Sotolongo Pena

IPC分类号： A61K9/08 ,  A61K9/14 ,  A61K9/19 ,  A61K38/00 ,  A61K38/18 ,  A61P9/10 ,  A61P17/02 ,  C07K14/485

CPC分类号： A61K38/1808

摘要： The invention relates to the use of Epidermal Growth Factor (EGF) in a preferably-injectable pharmaceutical composition which is administered by means of infiltration into and around chronic cutaneous ischaemic lesions in order to prevent diabetic foot amputation. Said composition can be administered to recently-created surgical surfaces damaged by the effect of acute reperfusion with oxygenated blood following prolonged ischaemia, thereby preventing further surgical procedures and favouring the preservation of the extremity. The aforementioned composition can be used to improve (i) the cell microenvironment, thereby increasing the reparative and defensive capacity and viability of the is tissues and (ii) the cicatrisation of cutaneous ischaemic lesions, thereby stimulating cell proliferation. The invention is suitable for use in human, veterinary and experimental medicine, specifically in vascular angiology and surgery, dermatology, burn treatment and reconstructive surgery and geriatric medicine. Said composition can be used for recalcitrant ulcers which are associated with lesions in the macro and/or microvasculature, patients with inadequate lymphatic and/or venous return and ulcers or other lesions which are difficult to cicatrise and/or heal.

摘要翻译： 本发明涉及在优选可注射的药物组合物中使用表皮生长因子（EGF），其通过渗入慢性皮肤缺血性损伤中及其周围而被施用，以防止糖尿病足部截肢。 所述组合物可以施用于由于长时间缺血引起的急性再灌注与氧合血液的影响而损伤的近期产生的手术表面，从而防止进一步的外科手术并有利于肢体的保存。 上述组合物可用于改善（i）细胞微环境，从而增加组织的修复和防御能力和活力，以及（ii）皮肤缺血性损伤的瘢痕化，从而刺激细胞增殖。 本发明适用于人类，兽医和实验医学，特别适用于血管病变和手术，皮肤病学，烧伤治疗和重建手术以及老年医学。 所述组合物可用于与宏观和/或微血管系统中的病变相关的顽固性溃疡，淋巴和/或静脉回流不足的患者以及难以发rise和/或愈合的溃疡或其它病变。

公开(公告)号：US06355414B1

公开(公告)日：2002-03-12

申请号：US09380790

申请日：2000-01-06

申请人： Julio Cesar Aguilar Rubido ,  Verena Lucila Muzio Gonzalez ,  Maria de Jesus Leal Angulo ,  Gerardo Enrique Guillen Nieto ,  Eduardo Penton Arias ,  Gloria Veliz Rios ,  Dagmara Pichardo Diaz ,  Antonieta Herrera Buch ,  Enrique Iglesias Perez ,  Luis Javier Cruz Ricondo ,  Tania Carmenate Portilla ,  Cirse Mesa Pardillo ,  Maydel Hechavarria Gay ,  Maylin Diaz Martinez ,  Juan Joel Madrazo Piñol

发明人： Julio Cesar Aguilar Rubido ,  Verena Lucila Muzio Gonzalez ,  Maria de Jesus Leal Angulo ,  Gerardo Enrique Guillen Nieto ,  Eduardo Penton Arias ,  Gloria Veliz Rios ,  Dagmara Pichardo Diaz ,  Antonieta Herrera Buch ,  Enrique Iglesias Perez ,  Luis Javier Cruz Ricondo ,  Tania Carmenate Portilla ,  Cirse Mesa Pardillo ,  Maydel Hechavarria Gay ,  Maylin Diaz Martinez ,  Juan Joel Madrazo Piñol

IPC分类号： C12Q170

CPC分类号： A61K39/095 ,  A61K39/12 ,  A61K39/292 ,  A61K2039/54 ,  A61K2039/543 ,  A61K2039/55544 ,  A61K2039/55583 ,  A61K2039/55588 ,  C12N2730/10134 ,  Y10S514/885 ,  Y10S977/906

摘要： The present invention is related to the field of medicine, particularly to the use of new adjuvant formulations with vaccine antigens. The technical objective pursued with this invention is, precisely, the development of formulations that are able to increase and/or modulate the immune response of the organism to vaccine antigens in the serum and the mucous lining. With this aim, a formulation was developed that contained as the main components the surface antigen of the hepatitis B virus and the acemannan in adequate proportions. As an extension of this result, formulations were developed in which a) HBsAg was used as the homologous or heterologous antigen carrier b) delivery systems of particulated antigens and c) soluble antigens, combined with the acemannan in specific proportions. The formulations of this invention are applicable in the pharmaceutical industry as vaccine formulations for human and veterinary use.

摘要翻译： 本发明涉及药物领域，特别是涉及使用具有疫苗抗原的新辅助制剂。 本发明追求的技术目标正是开发能够增加和/或调节生物体对血清和粘液衬里中的疫苗抗原的免疫应答的制剂。 为此，开发了一种配方，其中包含乙肝病毒的表面抗原和乙酰甘露聚糖的主要成分。 作为该结果的延伸，开发了其中a）将HBsAg用作同源或异源抗原载体b）颗粒抗原的递送系统和c）可溶性抗原与特定比例的acemannan结合的制剂。 本发明的制剂可用于制药工业，作为用于人类和兽医用途的疫苗制剂。